Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions

Lukasz Szyrwiel, József S. Pap, Wieslaw Malinka, Zbigniew Szewczuk, Aleksandra Kotynia, Justyna Brasun

Research output: Contribution to journalArticle

9 Citations (Scopus)


One of the treatments of Parkinson disease is based on increasing the brain dopamine level by L-DOPA (LD) applications. To prevent the peripheral degradation of levodopa, another drug, benserazide is applied. On the other hand, during this neurodegenerative disease changes in the homeostasis of metals are observed and the increasing brain zinc levels are postulated to have therapeutic effects. Here we present studies on interactions of Zn(II), Cu(II), Fe(II) ions with benserazide and with benserazide/levodopa in ternary system. By applying mass spectrometry and UV-vis methods we describe the interactions between selected metal ions and the drug additives in the investigated systems. The results show forming of equimolar complexes in the binary and ternary systems.

Original languageEnglish
Pages (from-to)36-43
Number of pages8
JournalJournal of Pharmaceutical and Biomedical Analysis
Publication statusPublished - Mar 5 2013


  • Benserazide
  • Interactions with metal ions
  • Mass spectrometry
  • Parkinson's disease
  • Stability

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science
  • Drug Discovery
  • Spectroscopy
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Interactions of anti-Parkinson drug benserazide with Zn(II), Cu(II), Fe(II) ions'. Together they form a unique fingerprint.

  • Cite this